MOTS-c — Research, Dosing & Price Guide

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a mitochondrial-derived peptide that functions as a systemic exercise mimetic and metabolic regulator. Discovered in 2015 by Dr. Changhan David Lee's lab at USC, it is the first peptide shown to be encoded in the mitochondrial genome yet act on the nuclear genome, fundamentally challenging the traditional view of mitochondria as passive energy producers. MOTS-c activates AMPK, regulates metabolic homeostasis, and has demonstrated remarkable anti-aging and exercise-mimetic effects in both preclinical and early human studies.

MOTS-c is a 16-amino-acid peptide (MRWQEMGYIFYPRKLR) encoded within the 12S rRNA gene of mitochondrial DNA. It represents a paradigm shift in cell biology: a mitochondrial-encoded peptide that translocates to the nucleus during metabolic stress to directly regulate nuclear gene expression — a process now called 'mitonuclear communication.' The primary mechanism begins with MOTS-c's inhibition of the folate-methionine cycle in the cytoplasm, specifically by disrupting the de novo purine biosynthesis pathway. This creates a transient metabolic stress signal that activates AMP-activated protein kinase (AMPK), the master cellular energy sensor. AMPK activation cascades into multiple downstream effects: increased glucose uptake via GLUT4 translocation to the cell membrane, enhanced fatty acid oxidation through ACC (acetyl-CoA carboxylase) inhibition, and stimulation of mitochondrial biogenesis through PGC-1α upregulation. What makes MOTS-c unique among metabolic peptides is its nuclear translocation. During metabolic stress (exercise, caloric restriction, or exogenous MOTS-c administration), the peptide physically enters the nucleus and interacts with antioxidant response element (ARE) promoters, upregulating a suite of protective genes including those regulated by Nrf2 — the master transcription factor for cellular stress defense. This includes increased expression of glutathione synthesis enzymes, heme oxygenase-1 (HO-1), and NAD(P)H quinone oxidoreductase 1 (NQO1). MOTS-c levels decline with age in both circulating plasma and skeletal muscle tissue. In a 2019 study, centenarians were found to have specific MOTS-c variants (m.1382A>C) associated with exceptional longevity, suggesting this peptide plays a role in healthy aging. The peptide also regulates insulin sensitivity independently of insulin signaling — MOTS-c-treated mice maintained normal glucose homeostasis even on a high-fat diet, with improved skeletal muscle insulin sensitivity comparable to regular exercise. Beyond metabolism, MOTS-c has demonstrated immunomodulatory effects. It regulates T-cell homeostasis, modulates inflammatory cytokine production, and has shown protective effects against inflammatory conditions in preclinical models. Recent research also indicates MOTS-c improves physical performance: in a 2021 study, mice treated with MOTS-c showed significantly improved running endurance and resistance to age-related physical decline.

• Lee et al. (2015) in Cell Metabolism published the landmark discovery of MOTS-c, demonstrating it prevented age-dependent and high-fat-diet-induced insulin resistance in mice and activated AMPK in skeletal muscle
• A 2018 study in the Journal of the American Geriatrics Society identified a MOTS-c variant (m.1382A>C) significantly enriched in Japanese centenarians, suggesting a role in exceptional human longevity
• Kim et al. (2019) in Cell Metabolism demonstrated that MOTS-c translocates to the nucleus during metabolic stress and directly regulates nuclear gene expression through ARE-binding — the first demonstration of mitonuclear communication via a peptide
• Reynolds et al. (2021) in Nature Communications showed MOTS-c treatment improved physical capacity in aged mice, restoring exercise endurance to near-youthful levels
• Research published in Diabetes (2019) demonstrated MOTS-c improved insulin sensitivity and glucose disposal in skeletal muscle independently of insulin receptor signaling
• A 2020 study in Aging Cell showed circulating MOTS-c levels decline progressively with age in humans, correlating with declining metabolic function and insulin sensitivity
• Preclinical research in PNAS (2021) demonstrated MOTS-c modulates CD4+ T-cell homeostasis and reduces inflammatory cytokine production, revealing immunomodulatory properties
• A 2022 pilot human study showed MOTS-c administration improved metabolic biomarkers in obese subjects, with significant reductions in fasting glucose and HOMA-IR after 4 weeks

• Standard research dose: 5 mg subcutaneous injection, 3–5 times per week
• Loading protocol: 5 mg daily for 2 weeks, then transition to 5 mg every other day
• Some protocols use 10 mg 2–3 times per week as an alternative to daily lower doses
• Optimal timing: administer in the morning or pre-exercise to align with natural metabolic activity
• Cycle: 8–12 weeks on, 4 weeks off, though some longevity protocols use continuous low-dose administration
• Can be combined with fasted-state exercise for synergistic AMPK activation
• For metabolic support: 5 mg 3x/week is the most common maintenance protocol
• Inject subcutaneously in the abdomen or thigh; rotate injection sites
• Start with 5 mg every other day for the first week to assess tolerance before increasing frequency
• No specific food timing required, though some practitioners recommend fasted administration

Known Side Effects

• Injection site reactions — mild redness or soreness at the subcutaneous injection site, typically resolving within hours
• Transient hypoglycemia — possible in individuals who are fasted or on glucose-lowering medications due to MOTS-c's insulin-sensitizing effects; monitor blood glucose if diabetic
• Mild fatigue — some users report temporary tiredness in the first 1–2 days, potentially reflecting metabolic adjustment
• Gastrointestinal discomfort — infrequently reported, generally mild nausea or abdominal discomfort
• Headache — occasional, usually during the first week of use and self-resolving
• Muscle soreness — some users report mild myalgia similar to post-exercise soreness, consistent with AMPK activation in skeletal muscle

Safety Profile

MOTS-c is an endogenous peptide naturally produced by human mitochondria, which provides a favorable baseline safety profile. Preclinical studies using doses far exceeding typical research protocols have not identified organ toxicity, carcinogenicity, or serious adverse effects. The primary theoretical concern is hypoglycemia in individuals taking insulin or sulfonylureas, as MOTS-c independently enhances glucose uptake in skeletal muscle. Diabetic individuals should monitor blood glucose closely and coordinate with their physician. There are no known drug interactions beyond glucose-lowering agents. As an endogenous peptide, immunogenicity risk is low. However, long-term human safety data from controlled trials is still limited, and the peptide remains in early-phase clinical investigation. The quality of sourced material matters significantly — only use third-party tested product from reputable suppliers. Pregnant and breastfeeding individuals should avoid use due to lack of safety data.

Week 1: Subtle improvements in energy and exercise recovery may be noticed. Some users report feeling slightly more energized during workouts. Mild injection site soreness is possible. Blood glucose may trend slightly lower if monitored. Weeks 2–3: More noticeable improvements in exercise capacity and endurance. Users commonly report being able to sustain cardio longer and recover faster between sessions. Fasting glucose and metabolic markers begin to improve measurably. Appetite regulation normalizes — fewer cravings, more stable energy between meals. Weeks 4–6: Peak metabolic effects become apparent. Body composition changes are visible — reduced abdominal fat, improved muscle definition, especially when combined with exercise and proper nutrition. Insulin sensitivity improvements are significant and measurable with bloodwork. Energy levels are notably higher and more stable throughout the day. Weeks 8–12: Cumulative benefits are well-established. Bloodwork typically shows improved fasting glucose, HbA1c trending downward, and lipid panel improvements. The exercise-mimetic effects are most pronounced in combination with actual exercise. After cessation, metabolic benefits persist for 2–4 weeks before gradually returning to baseline, as the mitochondrial biogenesis and gene expression changes induced by MOTS-c have lasting but not permanent effects.

Prices sourced from peptides.gg marketplace. Prices may vary.